Skip to main content

Advertisement

Table 6 Long-term trends in the proportion of subjects in each treatment arm who achieved a significant bronchodilator response for FEV 1 , FVC and either FEV 1 or FVC

From: Acute bronchodilator responses decline progressively over 4 years in patients with moderate to very severe COPD

  FEV FVC FEV or FVC
Tiotropium Placebo Tiotropium Placebo Tiotropium Placebo
Time N Proportion N Proportion N Proportion N Proportion N Proportion N Proportion
1 m 2535 0.42 2416 0.55 2535 0.47 2416 0.62 2535 0.59 2416 0.73
6 m 2515 0.42 2391 0.53 2515 0.44 2391 0.63 2515 0.57 2391 0.72
1 yr 2503 0.39 2382 0.53 2503 0.43 2382 0.63 2503 0.55 2382 0.72
1.5 yr 2380 0.40 2200 0.51 2380 0.43 2200 0.62 2380 0.56 2200 0.71
2 yr 2236 0.39 2040 0.49 2236 0.43 2040 0.60 2236 0.56 2040 0.69
2.5 yr 2132 0.39 1906 0.50 2132 0.42 1906 0.61 2132 0.55 1906 0.70
3 yr 2012 0.36 1792 0.47 2012 0.39 1792 0.59 2012 0.52 1792 0.69
3.5 yr 1894 0.36 1674 0.47 1894 0.41 1674 0.59 1894 0.52 1674 0.68
4 yr 1804 0.35 1599 0.47 1804 0.39 1599 0.56 1804 0.51 1599 0.66
Estimated OR (95% CI) for change in proportion per year* 0.92 (0.90, 0.94) 0.91 (0.89, 0.94) 0.93 (0.91, 0.95) 0.94 (0.92, 0.96) 0.92 (0.90, 0.94) 0.92 (0.90, 0.95)
p-value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
  1. *The OR (odds ratio) and its 95% CI were estimated with GEE methods using data starting from 1 m.
  2. FEV: Tiotropium vs. placebo p = 0.79.
  3. FVC: Tiotropium vs. placebo p = 0.60.
  4. FEV or FVC: Tiotropium vs. placebo p = 0.84.